Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes | Zendy

Jocelyne Piret | Zendy; Nathalie Goyette | Zendy; Guy Boivin | Zendy

Open Access

Drug Susceptibility and Replicative Capacity of Multidrug-Resistant Recombinant Human Cytomegalovirus Harboring Mutations in UL56 and UL54 Genes

Author(s) -

Jocelyne Piret,

Nathalie Goyette,

Guy Boivin

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01044-17

Subject(s) - foscarnet , cidofovir , virology , biology , human cytomegalovirus , ganciclovir , recombinant dna , mutant , mutation , gene , virus , cytomegalovirus , multiple drug resistance , drug resistance , herpesviridae , genetics , viral disease

Letermovir is an investigational antiviral agent with a novel mechanism of action involving the viral terminase (pUL56). We evaluated the impact of the V236M mutation in theUL56 gene alone and in combination with the E756K mutation in theUL54 gene on drug susceptibility and viral replicative capacity of recombinant human cytomegalovirus. The double mutant exhibited at least borderline resistance to all antivirals tested (ganciclovir, foscarnet, cidofovir, brincidofovir, and letermovir) and replicated less efficiently than the wild-type virusin vitro .

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research